Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB/IIA Study of Remestemcel-L, an Ex-vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product for the Treatment of Medically Refractory Crohn's Colitis

Next Previous
X
Search
Trial Profile

A Phase IB/IIA Study of Remestemcel-L, an Ex-vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product for the Treatment of Medically Refractory Crohn's Colitis

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Colitis; Crohn's disease
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 20 Feb 2022 According to a Mesoblast Limited media release, results of the first cohort of patients were published in the Journal of Crohn's and Colitis.
    • 20 Feb 2022 According to a Mesoblast Limited media release, results of the first cohort of patients were presented at the 17th Congress of European Crohn's and Colitis Organisation (ECCO).
    • 20 Feb 2022 Interim analysis results from the first patient cohort (n=12) presented in a Mesoblast Limited media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top